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Abstract
Background: Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that plays a role in DNA repair,
differentiation, proliferation, and cell death. The polymorphisms of PARP-1 have been associated with the risk of
various carcinomas, including breast, lung, and prostate. We investigated whether PARP-1 polymorphisms are
associated with the risk of non-Hodgkin lymphoma (NHL).
Methods: Subjects from a Korean population consisting of 573 NHL patients and 721 controls were genotyped for
5 PARP-1 polymorphisms (Asp81Asp, Ala284Ala, Lys352Lys, IVS13+118A>G, and Val762Ala) using High Resolution
Melting polymerase chain reaction (PCR) and an automatic sequencer.
Results: None of the 5 polymorphisms were associated with overall risk for NHL. However, the Val762Ala
polymorphism was associated with reduced risk for NHL in males [odds ratio (OR), 0.62; 95% confidence interval
(CI), 0.41-0.93 for CC genotype and OR, 0.84; 95% CI, 0.60-1.16 for TC genotype] with a trend toward a gene dose
effect (p for trend, 0.02). The Asp81Asp (p for trend, 0.04) and Lys352Lys (p for trend, 0.03) polymorphisms revealed
the same trend. In an association study of PARP-1 haplotypes, the haplotype-ACAAC was associated with decreased
risk of NHL in males (OR, 0.75; 95% CI, 0.59-0.94).
Conclusion: The present data suggest that Val762Ala, Asp81Asp, and Lys352Lys polymorphisms and the haplotype-
ACAAC in PARP-1 are associated with reduced risk of NHL in Korean males.
Background
Non-Hodgkin lymphoma (NHL) is the most common
hematologic malignancy worldwide. It represents 4% of
cancers, and is the fifth commonly diagnosed cancer in
the United States [1]. Its rates are over 10/100,000 in
the United States, Australia, and Western Europe, while
less than 5/100,000 in Southern and Eastern Asia [2].
PARP-1 is a nuclear enzyme that catalyzes the poly
(ADP-ribosyl)ation of target proteins in response to
DNA damage; it is involved in DNA repair, cell death,
proliferation, genome integrity, and modulation of gene
transcription [3,4]. PARP-1 is involved in base excision
reaction, which repairs DNA damage induced by
chemical alterations, reactive oxidative species, and
ionizing radiation. In addition, PARP-1 activation med-
iates apoptosis through the induction of translocation of
apoptosis-inducing factor from the mitochondria to the
nucleus [5].
The effect of PARP-1 on carcinogenesis is still unclear
and controversial. PARP-1 activation has been reported
to inhibit carcinogenesis by activation of DNA repair
system [6-13]. Parp deficiencies have enhanced tumori-
genesis and widened the tumor spectrum in p53-defi-
cient mice [10]. Treatment with the alkylating agent,
azoxymethane, enhanced the frequency of tumor
development in the colon and liver of Parp-1
-/- mice
[9]. Studies have demonstrated that PARP-1 Val762Ala
polymorphism is associated with an increased risk of
carcinomas, including prostate [8], esophagus [7], lung
[12], stomach [11], breast [13], and urinary bladder [6].
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absence of PARP-1 is associated with reduced risk of
malignancy by inducing tumor cell apoptosis [14-18].
Loss of Parp-1 has increased tumor latency in p53-defi-
cient mice [14]. Parp-1
-/- mice displayed a diminished
susceptibility to skin carcinogenesis compared with
Parp-1
+/+ mice after treatment with 7,12-dimethylbenz
[a]-anthracene and 12-O-tetra-decanoyl-phorbol-
13-acetate [17]. PARP-1 polymorphisms have been
associated with reduced risk of malignancy in several
case-control studies [15,16,18]. However, others have
also proposed that PARP-1 has no effects on tumor
development [19,20]. Parp-1
-/- mice did not demonstrate
an increased incidence of tumor formation after either
4-nitroso-quinoline or 2-amino-3-methylimidazo treat-
ment [19]. In a case-control study in Connecticut
women, the risk of NHL was not associated with
PARP-1 Val762Ala polymorphism [20].
Although many studies have searched for the associa-
tion between PARP-1 polymorphisms and the risk of
malignancy, the results are inconsistent in different
organs and in different ethnic groups. We performed a
population-based, case-control study to identify the
association between PARP-1 polymorphisms and NHL
risk in Korean subjects.
Methods
Study population
This case-control study included NHL patients
(n = 573) and cancer-free controls (n = 721). All cases
and controls were unrelated Korean individuals; the cases
were adults (median age at diagnosis ± S.D 55.0 ± 14.6
years, range 15.0-90.0 years), histologically diagnosed
with NHL between 1997 and 2006 at Chonnam National
University Hospital (Gwangju, Korea) or Chonnam
National University Hwasun Hospital (Hwasun, Korea)
[21]. Lymph nodes or extranodal tissues were obtained
and histologically diagnosed according to the World
Health Organization (WHO) classification [22]. A staging
workup included physical examination, laboratory exami-
nation, computed tomography scan, bone marrow biopsy,
and lumbar puncture. Stages were defined according to
the Ann Arbor system [23]. Types of NHL included
diffuse large B-cell lymphomas (n = 330), T-cell lympho-
mas (n = 122), and other lymphomas (n = 121). The
controls were frequency matched to patients by age
within 5 years, sex, and county of residence. All of the
healthy controls have no history of cancer (427 males,
304 females; median age ± S.D. 56.0 ± 15.3 years, range
17.0-82.5 years) (Table 1). All cases and controls
provided informed consent for study participation. The
study was approved by the Institutional Review Board of
the Chonnam National University Hwasun Hospital in
Hwasun, Korea.
Genotyping
Genomic DNA was obtained from peripheral blood
using a QIAamp DNA Blood Mini Kits (Qiagen,
Valencia, CA, USA) according to the manufacturer’s
protocols. PCR cycling and high resolution melting
(HRM) analysis was performed on the Rotor-Gene
6000™ (Corbett Research, Sydney, Australia) [24]. The
PCR primers were as follows: for Val762Ala (86 bp
fragment), 5’-taagtcgggggctttctttt-3’ (forward), and
5’-agcagactgtaggccacctc-3’ (reverse); for Asp81Asp (160 bp
fragment), 5’-gatgggttctctgagcttcg-3’ (forward), and 5’-
gaggtttgctttgctctctga-3’ (reverse); for Ala284Ala (76 bp
fragment), 5’-gccctctgacatgtttctcc-3’ (forward), and 5’-aag-
gagggcaccgaacac-3’ (reverse); for Lys352Lys (178 bp
fragment), 5’-caagggagagctggcttctt-3’ (forward), and
5’-ggagttcacagcagcagga-3’ (reverse); for IVS13+118A>G
(124 bp fragment), 5’-tggatcaggtggcatcatag-3’ (forward),
and 5’-ggtactggccttcatgcaat-3’ (reverse). The reaction mix-
ture included genomic DNA (10 ng), 1× PCR buffer,
2.5 mM MgCl2, primers (100 nM), dNTPs (100 μM),
SYTO 9 green fluorescent nucleic acid stain (2.5 μM; Invi-
trogen, Carlsbad, CA, USA), Taq. polymerase (0.5 U;
Table 1 Frequency distribution of selected characteristics
of study subjects According to case-control status
Characteristic Cases Controls P value
No.(%) 573 (100) 721 (100)
Age, no.(%)
15-49 y 179 (31.2) 201 (27.9)
50-64 y 226 (39.4) 286 (39.7
≥ 65 y 168 (29.3) 234 (32.5) 0.33
Mean(yr.) ± SD 55.0 ± 14.6 56.0 ± 15.3
Range 15.0-90.0 17.0-82.5
Sex
Male 336 (58.6) 417 (57.8)
Female 237 (41.4) 304 (42.2) 0.77
NHL tumor pathology
All B-cell lymphoma 451 NA NA
Diffuse large B-cell 330 NA NA
Marginal zone* 69 NA NA
Follicular 17 NA NA
Mantle cell 12 NA NA
Small lymphocytic 8 NA NA
Burkitt lymphoma 3 NA NA
Others
B 12 NA NA
All T-cell lymphoma 122 NA NA
Peripheral T-cell 55 NA NA
Others
T 67 NA NA
P values for differences in socio-demographic characteristics between cases
and controls.
NA indicates not applicable. Marginal zone* includes marginal zone B-cell
lymphoma (n = 12) and mucosa-associated lymphoid tissue (MALT) (n = 57).
Others
B includes B-cell prolymphocytic leukemia (n = 1) and undetermined
B-cell lymphoma (n = 11). Others
T includes all T-cell lymphoma (n = 67)
except for peripheral T-cell lymphoma.
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10 μl. Cycling conditions included an initial 5 min hold at
95°C, followed by 40 cycles at 95°C for 5 s, annealing tem-
peratures for 30 s, and 72°C for 20 s; a single cycle of 95°C
for 1 s, 72°C for 90 s, and melting increasing from 70°C to
90°C at 0.1°C per second. Annealing temperatures for
Asp81Asp, Ala284Ala, Lys352Lys, Val762Ala and IVS13
+118A>G were 62°C, 56°C, 58°C, 56°C, and 60°C,
respectively.
PCR products were column-purified after HRM analy-
sis using the PCR-M clean up kit (GeneAll Biotechnol-
ogy, Seoul, Korea) according to the manufacturer’s
instructions. PCR products were eluted in a 20 μl
volume, purified PCR products were used as templates
in the Big Dye Terminator v3.1 Cycling Sequencing kit
(Applied Biosystems, Foster City, CA, USA). The reac-
tion mix consisted of 1× terminator pre-mix, 1× sequen-
cing buffer, primers (667 nM), and purified template (1
μl) in a 10 μl total volume. Reactions were run on a
PTC-100 thermal cycler (MJ Research, Reno, NV, USA)
as follows: a single cycle of 95°C for 1 min, 25 cycles of
95°C for 10 s, 50°C for 5 s, and 60°C for 4 min. Sequen-
cing reactions were ethanol-precipitated and run on a
3100 Genetic Analyser (Applied Biosystems). In 90 sub-
jects, the results of HRM analyses were compared with
those from cycle sequencing, and the resulting concor-
dance rate was 100%.
Statistical analysis
Hardy-Weinberg equilibrium testing was performed
using the chi-square goodness-of-fit test. The Pearson
chi-square test was used to examine the genotype distri-
bution differences between cases and controls. Adjusted
odds ratios (ORs) were calculated using a logistic regres-
sion model that controlled for gender and age and
included 95% confidence intervals (CIs). Statistical sig-
nificance was defined at p values less than 0.05, and all
statistical tests were 2-sided. Haplotypes and haplotype
frequencies were calculated using the SNPAnalyzer-Pro
version 1.8 software (Istech, Goyang, Korea) to analyze
associations between haplotypes and NHL risk after
stratification by age at diagnosis, sex, and NHL subtype.
All calculations were performed using an SPSS software
package, version 13.0 (SPSS, Chicago, IL). PARP-1 inter-
SNP linkage disequilibrium was calculated using Haplo-
view software version 4.1 http://www.broad.mit.edu/
mpg/haploview for the set of control samples (n = 721).
Results
Characteristics of the study population are summarized
in Table 1. There were no differences in the frequency
distribution for age (p =0 . 3 3 )o rs e x( p = 0.77) between
cases and controls. The control genotype distributions
were in agreement with the Hardy-Weinberg
equilibrium (p =0 . 6 1f o rA s p 8 1 A s p ,p = 0.31 for
Ala284Ala, p = 0.83 for Lys352Lys, p =0 . 3 8f o rI V S 1 3
+118 A>G, p = 0.84 for Val762Ala). Haploview version
4.1 determined that the PARP-1 locus contained 1 block
of linkage disequilibrium (Figure. 1). Two groups of
polymorphisms were present in the block; one group
consisted of Asp81Asp, Lys352Lys, and Val762Ala poly-
morphism, and the other included Ala284Ala and IVS13
+118A>G polymorphism. Both revealed high intra-
group linkage disequilibrium (r
2, ≥ 0.96), but low inter-
group linkage disequilibrium (r
2, 0.22-0.23).
Table 2 summarizes the association study between the
5 polymorphisms and the overall risk for NHL. Analysis
revealed no significant associations between polymorph-
isms and overall NHL risk. Neither the CC genotype of
Val762Ala (OR, 0.85; 95%CI, 0.62-1.17) nor the TC gen-
otype (OR, 0.93; 95%CI, 0.72-1.19) were associated with
risk for NHL. The genotypes of the remaining 4 poly-
morphisms were also associated with risk for NHL.
As presented in Additional file 1: table S1, males with
the TC genotype of Val762Ala demonstrated a slightly
reduced NHL risk (OR, 0.84; 95% CI, 0.60-1.16) com-
pared to those with the TT genotype. And the males
with the CC genotype had a significantly reduced risk
(OR, 0.62; 95% CI, 0.41-0.93) which revealed a trend
toward a gene dose effect (p for trend, 0.02). However,
there was no association between Val762Ala polymorph-
ism and NHL risk in females. There was significant
interaction seen between sex and the Val762Ala poly-
morphism (p for interaction, 0.048). Asp81Asp (p for
trend, 0.04) and Lys352Lys (p for trend, 0.03) poly-
morphisms revealed similar trends, although interactions
between sex and polymorphism were a borderline signif-
icance levels (p for interaction of Asp81Asp, 0.062; p for
interaction of Lys352Lys, 0.067). However, PARP-1 poly-
morphisms did not show associations with the NHL
subtypes (Additional file 1: table S2) or age (data not
shown).
The distribution of PARP-1 haplotype frequencies and
association of haplotypes with risk for NHL are sum-
marized in Additional file 1: table S3. Three common
haplotypes (ACAAC, GCGAT, and GTGGT) and several
rare ones (with frequency < 5%) were inferred, and rare
haplotypes were excluded in the association analyses.
None of the haplotypes were associatied with overall
risk for NHL. However the haplotype-ACAAC in males
was associated with decreased risk for NHL (OR, 0.74;
95% CI, 0.59-0.94) when haplotype-GCGAT was used as
a reference.
Discussion
We investigated the association between 5 PARP-1 poly-
morphisms and NHL risk in a Korean population. Three
polymorphisms (Asp81Asp, Lys352Lys, and Val762Ala)
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association testing of haplotype-ACAAC revealed a simi-
lar result. However, none of the PARP-1 polymorphisms
or haplotypes were associated with overall NHL risk.
Our data appear to support the hypothesis that accumu-
lated DNA damage may lead to enhanced apoptosis dur-
ing cell division, which could result in protection from
development of malignancy with intact apoptotic mechan-
isms. Concordant findings with the results of this study
have been identified in case-control studies of squamous
cell carcinoma of the head and neck [15], breast carci-
noma [18], and adult glioma [16]. In animal experiments,
overexpression of dominant negative PARP-1 prevented in
vivo tumor formation by HeLa cells in nude mice due to
increased apoptosis of tumor cells [25].
PARP-1 polymorphisms were associated with
decreased risk of NHL in males in this study. The sexual
dimorphism might be associated with the female sex
hormone, 17-b-estradiol. PARP strongly interacts with
estrogen receptor a and DNA in the presence of
17-b-estradiol, which leads to inhibition of PARP activa-
tion [26]. Sex-dependent response to PARP activation
has also been reported in an endotoxin-induced inflam-
mation and vascular change model, female mice were
more resistant to endotoxin than male mice[26]. In a
neonatal-stroke mouse model, disruption of the PARP-1
gene selectively protected male mice against brain injury
[27]. Also in an adult-stroke mouse model, female neu-
ronal nitric oxide synthase knockout (nNOS-/-) mice
were more severely damaged after middle cerebral artery
occlusion than wild-type females. In addition, male
nNOS-/- littermates were protected [28]. In a case-con-
trol study, PARP-1 polymorphism has been associated
with reduced risk of adult glioma in men [16].
Figure 1 PARP-1 inter-polymorphism linkage disequilibrium. PARP-1 inter-polymorphism linkage disequilibrium. r
2 between pairs of
polymorphisms was calculated based on all the controls using Haploview v4.1 http://www.broad.mit.edu/mpg/haploview.
Jin et al. BMC Medical Genetics 2010, 11:38
http://www.biomedcentral.com/1471-2350/11/38
Page 4 of 6Inconsistency of the association between PARP-1 poly-
morphism and malignancy risk might result from differ-
ences in genetic background, environmental factors,
organ specificity, and study sample size. For example, the
frequency of the Val762Ala genetic polymorphism differs
between ethnic groups. In the present study of Koreans,
the frequency of the C allele is 0.448 which is consistent
with that observed in previous studies of Koreans (0.444)
and Han Chinese (0.389) [12,29]. However, the frequency
is 0.145 in Caucasian-Americans and 0.045 among
African-Americans [8]. PARP-1 expression levels vary in
carcinomas of different organs. It is high in lymphoma
[30] and endometrial carcinoma [31], and low in breast
carcinoma [32,33] and laryngeal carcinoma [34].
In this present study, haplotype-ACAAC was also
associated with reduced risk of NHL in males, although
there was no association between any haplotypes and
overall NHL risk. It agrees with the results that the A
allele of Asp81Asp, A allele of Lys352Lys, and C allele
of Val762Ala are significantly associated with decreased
risk of NHL.
A st h es a m p l es i z eo ft h i ss t u d yi sn o ts u f f i c i e n t l y
large and is restricted to Korean population, the present
data should be validated in larger samples and in other
ethnic groups. Although PARP-1 polymorphisms are
associated with decreased risk of NHL in the present
study, we could not exclude the possibility that other
un-typed variants located in or near the PARP-1 locus
might be associated with reduced risk of NHL. Addi-
tional surveys examining other variants around the
locus are required to resolvet h i si s s u e .Ag e n e - g e n e
interaction study examining genes involved in apoptosis
or DNA repair might allow for a more comprehensive
perspective.
Conclusion
In a polulation-based, case-control study to identify the
association between polymorphisms in PARP-1 and
NHL risk in Koreans, we found that Val762Ala,
Asp81Asp, and Lys352Lys polymorphisms and the hap-
lotype-ACAAC in PARP-1 were associated with
decreased risk of NHL in males.
Additional file 1: Supplemental tables S1, S2 and S3.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2350-11-
38-S1.DOCX]
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